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Abstract
Background: There is growing evidence of an interaction between HIV-infection, anti-retroviral therapy (ART) and
cardiovascular diseases (CVD). Epidemiological studies in Europe and North America have been observing a shift
towards an increased incidence of coronary heart disease and acute myocardial infarctions in HIV-infected populations
compared to the general population even after adjusting for traditional cardiovascular risk factors. Despite South Africa
(and sub-Saharan Africa, SSA) being regarded as the epicentre of the global HIV epidemic, very little is known about
the prevalence of cardiovascular risk factors and precursors of vascular disease in HIV-infected populations in this
region. The knowledge gap is further widened by the paucity of data from prospective studies. We present the
rationale, objectives and key methodological features of the EndoAfrica study, which aims to determine whether HIV-
infection and ART are associated with altered cardiovascular risk and changes in vascular endothelial structure and
function in adults living in the Western Cape Province of South Africa.
Methods: In this longitudinal study, comprehensive cardiovascular assessments of HIV-negative and HIV-positive (with
and without ART) study participants are performed by clinical and biochemical screening for traditional cardiovascular
risk factors and biomarkers of CVD. Vascular and endothelial function is determined by brachial artery flow-mediated
dilatation (FMD), carotid-intima-thickness (IMT) measurements and quantitative retinal blood vessel analyses,
complemented by vascular endothelial biomarker assays. Finally, we aim to statistically determine whether HIV-
infection and/or ART are associated with increased cardiovascular risk and vascular endothelial dysfunction, and
determine whether there is progression/regression in these endpoints 18 months after the baseline assessments.
Discussion: The EndoAfrica study provides a unique opportunity to recruit a cohort of HIV-infected patients and HIV-
negative controls who will be comprehensively and longitudinally assessed for cardiovascular risk and disease profile
with vascular endothelial function as a potentially important intermediate cardiovascular phenotype. To our
knowledge, it is the first time that such a systematic study has been established in the context of SSA and South Africa.
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Background
There is growing evidence of an interplay between HIV-
infection, anti-retroviral therapy (ART) and cardiovascular
diseases (CVD) [1]. The trends with regards to the nature
of HIV-related CVD have evolved since the introduction
of highly active ART (HAART). HIV-associated cardiomy-
opathy was one of the first CVD conditions described in
HIV-infected study populations [2–5], with systolic dys-
function particularly prevalent in the pre-HAART era.
Since the introduction of HAART, epidemiological studies
in Europe and North America have been observing a shift
towards an increased incidence of coronary heart disease
in HIV-infected populations compared to the general
population [1, 6–8]. For example, a large prospective co-
hort study in the USA with ~82,000 participants showed
that HIV-infected participants had a 50% increased risk of
acute myocardial infarction even after adjusting for trad-
itional cardiovascular risk factors [9].
Sub-Saharan Africa (SSA) is home to approximately 26-
million (70%) of the world’s HIV-infected population [10].
As a result, SSA has witnessed the roll-out of massive
ART programmes in recent years. For example, South Af-
rica has the world’s largest Government-sponsored
programme that reached approximately 3.1-million people
in 2015 [11]. In addition to the HIV/AIDS epidemic, many
countries in SSA are subjected to a rapidly expanding
non-communicable diseases epidemic, characterised by,
among others, a high prevalence of traditional cardiovas-
cular risk factors and disease [12]. In fact, it has been re-
ported that 80% of all cardiovascular-related deaths
globally occur in low- to middle income countries [13]. In
South Africa, the growing prevalence of traditional cardio-
vascular risk factors such as hypertension, obesity and dia-
betes mellitus has been described as a “time bomb” [14],
and the multiple burden of communicable and non-
communicable diseases a “collision of epidemics” [15].
Surprisingly, the impact of high HIV-infection rates and
HAART on the increasing prevalence of CVD in SSA has
received relatively little research attention and the know-
ledge gap is further widened by the paucity of data from
longitudinal studies.
Based on the limited epidemiological data available,
pulmonary hypertension, cardiomyopathy and tubercu-
lous pericarditis are reported to be the most common
cardiovascular-related pathologies associated with HIV-
infection in SSA populations [12, 16]. The incidence of
coronary artery disease in SSA is relatively low, not only
in the general population [17], but seemingly also in
people affected by HIV-infection [18]. However, there is
reason to believe that the current predominantly “pre-
HAART” cardiovascular disease profile of sub-Saharan
Africans living with HIV/AIDS may change. Taking into
account the increase in coronary artery disease observed
in HIV-infected populations from Europe and USA since
the introduction of HAART, it is conceivable that the
full cardiovascular health impact of the HAART roll-
out programmes initiated in SSA in recent years has
not yet been felt [12]. In this regard, data are emer-
ging from countries such as Kenya and South Africa
showing a higher incidence of traditional (predomin-
antly pro-atherogenic) cardiovascular risk factors, such
as hypertension, obesity and dyslipidaemia in HIV-
infected participants [19–21].
Vascular endothelial activation and endothelial dysfunc-
tion are now recognized as early markers of HIV-related
CVD [1, 22, 23], and recent data from South Africa con-
firmed that HIV-infection was associated with increased
inflammation-induced endothelial injury, endothelial acti-
vation, and endothelial dysfunction [24, 25]. Vascular
endothelial changes occur early in the cardiovascular dis-
ease process, and endothelial dysfunction is widely recog-
nized as a marker of the net effects of cardiovascular risk
factors as well as future cardiovascular events [26]. Hence,
the inclusion of vascular endothelial function assessment
as a surrogate marker of CVD in clinical research in SSA
populations has recently been advocated [27, 28].
Problem statement
The HIV/AIDS epidemic in SSA appears to be on a col-
lision course with the rapidly increasing burden of car-
diovascular risk factors and disease. However, the scope
and nature of the cardiovascular risk and disease profile,
including early vascular and endothelial changes, of
HIV-infected populations in SSA remains unclear.
Hence, the need for epidemiological studies to address
this knowledge gap is great. Studies should screen for
traditional endpoints of cardiovascular risk in HIV/
AIDS-exposed populations, and also incorporate end-
points that provide early (preclinical) and predictive in-
formation on cardiovascular risk and future events, such
as vascular endothelial function measurements.
The EndoAfrica study was established to provide a
comprehensive and repeated assessment of the cardio-
vascular risk and disease profile in South African adults
living with HIV/AIDS. The study includes clinical
screening and extensive biomarker analysis of vascular
endothelial function. To our knowledge, it is the first
time that such a systematic study has been established
in the context of SSA and South Africa.
Methods/design
Aim and objectives
The overarching aim of the EndoAfrica study is to deter-
mine whether HIV-infection and ART are associated
with altered cardiovascular risk and changes in vascular
endothelial structure and function in adults living in the
Western Cape Province of South Africa. The following
objectives have been defined:
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1. To perform comprehensive cardiovascular
assessments of HIV-negative and HIV-positive (with
and without ART) study participants by clinical and
biochemical screening for traditional cardiovascular
risk factors (overweight/obesity, smoking, hyperten-
sion, diabetes mellitus, dyslipidaemia) and bio-
markers of CVD;
2. To perform assessments of vascular and endothelial
function by ultrasound-based flow-mediated dilata-
tion (FMD) measurements of the brachial artery,
carotid-intima-thickness (IMT) measurements,
quantitative retinal blood vessel analysis, and vascu-
lar endothelial biomarker analyses;
3. To determine statistically whether HIV-infection
and/or ART are associated with increased cardiovas-
cular risk and vascular endothelial dysfunction, and
determine whether there is progression/regression in
these endpoints 18 months after the baseline
assessments.
Study design and setting
EndoAfrica uses a repeated measures design, and study
participants undergo baseline and 18 months’ follow-up
assessments. Assessments include a personal interview
and completion of a comprehensive health question-
naire, standard anthropometric measurements, a cardio-
vascular system-focused physical examination, blood and
urine collection for biochemical and biomarker analyses,
ultrasound-based vascular and endothelial assessments
(FMD and carotid IMT), and fundus imaging for retinal
blood vessel analysis. The study allows the investigators
to monitor the progression or regression of the major
study endpoints in participants over a 18-month period.
EndoAfrica, which commenced officially in April 2015,
has received ethics approval from the relevant body at
Stellenbosch University (see later) and is conducted in
Cape Town and Worcester in the Western Cape Prov-
ince of South Africa.
Participant recruitment and study groups
The study population mainly consists of patients visiting
primary health care clinics. Participants are recruited by
qualified and experienced research nurses at commu-
nity health care centres and/or HIV clinics in Cape
Town (Elsies River, Adriaanse, Fisantekraal, Uitsig, Dur-
banville and Ravensmead), and the local community
health centre in Worcester based on pre-determined
inclusion and exclusion criteria. For inclusion into the
study, participants must be 18 years or older, and fe-
male participants must not be pregnant or less than
3 months post-partum. Participants will be excluded
from the study if they are younger than 18 years, preg-
nant, or less than 3 months post-partum. Participants
who qualify for inclusion are invited to take part in the
study and requested to sign an informed consent form.
Once enrolled, participants with unknown HIV status
are counselled for HIV testing and screened for HIV-
infection by performing a rapid HIV test (SD Bioline
HIV 1/2 3.0 immunochromatographic test kit; Standard
Diagnostics, Republic of Korea). If the test result is nega-
tive, the participant is assigned to the HIV-negative con-
trol group. Participants with confirmed HIV-infection
are assigned to the HIV-positive group, which is further
divided into two sub-groups based on the ART status of
participants. Those participants not receiving ART are
assigned to the “HIV-positive ART naïve” sub-group.
Current South African ART guidelines recommend that
all newly diagnosed HIV-infected patients be placed on
ART regardless of their CD4 count. In view of this, one
has to realistically assume that the majority of partici-
pants in this sub-group will likely commence with ART
soon after recruitment. This provides a unique oppor-
tunity to assess cardiovascular risk and early endothelial
changes in both the untreated (baseline) and treated
(18 months’ follow-up) state in the same participants.
Therefore, the effects of ART can be assessed in individ-
uals who serve as their own untreated controls. The sec-
ond sub-group consists of HIV-infected participants
who have been on ART for at least four weeks (“HIV-
positive on ART”). The CD4 count and viral load of the
HIV-positive participants will be determined at baseline
and 18 months’ follow-up. All participants are required
to fast from 22 h00 the night before the assessments.
They are also asked to refrain from smoking, drinking
coffee or doing exercise for 4–6 h prior to the study, and
female participants should report the phase of their
menstrual cycle. Figure 1 depicts the study design, inclu-
sion/exclusion criteria and study groups.
Assessments: clinical and laboratory investigations
Health questionnaire, anthropometry, cardiovascular
measurements, blood and urine chemistry
General cardiovascular health information is obtained from
questionnaires and personal interviews (including family
and personal history of cardiovascular disease, medication,
smoking, and alcohol consumption). In addition, partici-
pants are screened for cardiovascular risk factors by an-
thropometric measurements, heart rate and blood pressure
measurements, and blood and urine chemistry analyses.
The anthropometric assessments, viz. body-mass-index
(BMI), waist circumference and waist-to-hip ratio, are per-
formed according to international standards [29]. Heart
rate and brachial systolic and diastolic blood pressure of
the left arm are measured at three different occasions, 2–
5 min apart, with an Omron M6 automatic digital blood
pressure monitor (Omron Healthcare, Kyoto, Japan). Blood
and early morning mid-stream urine samples are obtained
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by the research nurse from each participant. Samples are
transported to the National Health Laboratory Service
(NHLS) laboratory in the Tygerberg Academic Hospital,
adjacent to the Faculty of Medicine and Health Sciences of
Stellenbosch University. Here, the following markers of car-
diovascular risk are measured: (i) Lipids (total cholesterol,
LDL-cholesterol, HDL-cholesterol and triglycerides), (ii)
glucose, (iii) glycated haemoglobin (HbA1c), (iv) creatinine,
(v) gamma-glutamyl transferase (GGT), (vi) highly sensitive
C-reactive protein (hs-CRP), (vii) haemoglobin, and (viii)
urine albumin : creatinine ratio. The measurements are per-
formed according to NHLS approved standard analytical
protocols. Collectively, results from the above interviews
and investigations allow the researchers to screen for the
following cardiovascular risk factors: smoking, alcohol con-
sumption, overweight/obesity, hypertension, diabetes melli-
tus, dyslipidaemia, renal impairment, inflammation and
liver disease.
Flow mediated dilation (FMD)
FMD is regarded as the gold standard of noninvasive
vascular endothelial function assessment in the research
setting [26, 30]. Several studies have been performed in
which FMD measurement of vascular endothelial func-
tion was validated in terms of prognostic ability as well
as successful disease progression/regression monitoring
in clinical trials [30]. FMD has also previously been
shown to be a marker of effect in populations living with
HIV/AIDS [31, 32].
The FMD procedure used in the EndoAfrica study is
based on a previously described protocol [30], and per-
formed by research assistants who have been trained by
specialists in the field. According to the protocol, the
participant rests in the supine position for 10 min prior to
the procedure. A longitudinal image of the right brachial ar-
tery is obtained in B-mode with an Esaote MyLabTMFive
ultrasound and 12 MHz linear probe (Esaote, Italy). The
probe is stabilised on the upper-arm using a single axis pre-
cision probe holder from SMT Medical (Wuerzburg,
Germany) that allows for micro-metric adjustments. Dop-
pler mode is used to visualise and locate the brachial artery
with pulse repetition frequency (PRF) set at 6.7 kHz. Once
the artery is properly visualised, depth is increased to 3 cm
before switching to pulse wave mode. In pulse wave mode,
the angle of insonation is set to +60°. Brachial artery diam-
eter and shear rate measures are recorded continuously
with FMD Studio and Cardiovascular Suite version 2.8.1
software (Quipu, Italy), which makes use of automatic edge
detection technology. The protocol starts with 1 min base-
line recording at rest. Following this, a blood pressure cuff
around the fore-arm is inflated to 50 mmHg above the sys-
tolic blood pressure value and remains inflated for 5 min,
this is called the ischaemic phase. After 5 min, the cuff is
deflated resulting in hyperaemia and increased shear rate
inducing endothelium-dependent dilatation of the brachial
artery, followed by the recovery phase (total recording time:
3 min). At the end of the procedure, the software calculates
baseline artery diameter, maximum artery diameter, recov-
ery artery diameter, FMD % (difference between maximum
and baseline diameter expressed as %), baseline shear rate
and maximum shear rate.
Carotid intima-media thickness (IMT)
Carotid IMT is an important biomarker of arterial wall
thickening and subclinical and clinical atherosclerosis
[33, 34]. Increases in IMT are associated with both
Fig. 1 Recruitment protocol and study groups
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prevalent and incident cardiovascular morbidity and
mortality, including coronary heart disease [35]. IMT
measurements will follow protocols and guidelines as
described previously [36]. The participants are in the su-
pine position with the head tilted 30° to the left for as-
sessment of the right carotid artery, and 30° to the right
for assessment of the left carotid artery with the Esaote
MyLabTMFive ultrasound and 12 MHz linear probe
(Esaote, Italy). Once the carotid artery bifurcation is
visualised manually in b-mode, a 10 mm straight arterial
segment is selected in the common carotid artery prox-
imal to the bifurcation bulb. The segment must be free
of atherosclerotic plaque and the lumen-intima and
media-adventitia interfaces must be clearly defined. Ded-
icated Quality Intima-Media Thickness (QIMT) software
is used for real-time radio frequency detection of the
IMT, which automatically measures the intima-media
thickness. The software additionally calculates the me-
dian ± standard deviation IMT values during several car-
diac cycles [37].
Retinal vessel analyses
Retinal image analysis is an unobtrusive procedure for
visualizing the microcirculation. The microcirculation
consists of blood vessels less than ~150 μm and includes
smallest resistance arteries, arterioles, capillaries, and ve-
nules. These vessels make up a large part of the circula-
tory system and play an important role in maintaining
cardiovascular health. There is substantial evidence in
favour of a correlation between retinal vascular changes
and coronary heart disease [38, 39]. The ratio between
the diameter of retinal arteries and retinal veins (A/V)
has been shown to be a sensitive proxy to reflect hyper-
tension and atherosclerosis [40]. A narrowing of the ar-
teries and widening of the veins, leading to a decreased
A/V ratio, corroborates with risk of stroke and myocar-
dial infarction [41]. Quantitative features extracted from
retinal images have been proven useful for identifying
microvascular changes with predictive power in the field
of cardiovascular disease development [42].
Fundus images are captured with a non-mydriatic
digital retinal camera (Canon CR-2 camera, Canon Eur-
opa NV, The Netherlands). The retinal vessel dimen-
sions, vascular tree and microvascular state are analysed
with semi-automated IFLEXIS software developed by
VITO (Belgium). Analysis of retinal images are under-
taken by a trained grader, masked to participant charac-
teristics. The grader performs the vessel measurements
on the optic disc–centred image of both the right and
left eye; however, the data of the right eye are used for
most participants and left eye data only when the right
eye images are ungradable. The software allows calculat-
ing vessels widths and pattern features. For the calcula-
tion of vessel width, the largest six arterioles and venules
coursing through a zone between 0.5 and 1 disc diam-
eter from the optic disc margin are measured. Estimates
are summarized as central arteriolar equivalent (CRAE)
and central retinal venular equivalent (CRVE), represent-
ing the average diameter of arterioles and venules of the
eye, respectively [43]. For the calculation of pattern fea-
tures such as tortuosity, fractal analysis, and lacunarity,
all blood vessels coursing through a zone of 2x disc
diameter from the optic disc margin are measured. An
overview of the different retinal features that are calcu-
lated are also reported in a recent study by Prabhakar
and colleagues [44].
Serum biomarker analyses
An array of serum biomarkers of vascular endothelial dys-
function will be measured to complement the clinical
measurements. The following biomarkers have previously
been shown to be associated with vascular endothelial
dysfunction, and will be measured in this study: vascular
cellular adhesion molecule-1 (VCAM-1), intercellular
adhesion molecule-1 (ICAM-1), e-selectin, p-selectin,
platelet activating inhibitor-1 (PAI-1), tumor necrosis
factor-alpha (TNF-α), vascular endothelial growth factor
(VEGF) and von Willebrand Factor [22]. These markers
will be measured by Luminex technology (Luminex Bio-
Plex 200 system) in the Division of Molecular Biology and
Human Genetics, Faculty of Medicine and Health Sci-
ences, Stellenbosch University. The Luminex cytokine/
chemokine/protein assays are sandwich immunoassays
that are performed in 96-well filter plates, similar to sand-
wich ELISA assays, and can analyse up to 100 different
host markers in each well.
Figure 2 shows the baseline and 18 months’ follow-up
assessments.
Data collection, management and statistical analysis
All data generated from the health questionnaires, clinical
assessments and biochemical investigations will be col-
lected and managed using REDCap electronic data capture
tools hosted at the Department of Biomedical Sciences,
Fig. 2 Clinical and biochemical assessments of study participants at
baseline and 18 months’ follow-up
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Stellenbosch University [45]. REDCap (Research Electronic
Data Capture) is a secure, web-based application designed
to support data capture for research studies.
Data are statistically analyzed in conjunction with the
Biostatistics Unit in the Centre for Evidence-based
Health Care, Stellenbosch University. Descriptive statis-
tical models (ANOVA, Chi Square) will be used for
inter-group comparisons, and associations between inde-
pendent and dependent variables will be tested by multi-
variate regression analysis models, adjusting for age,
gender, ethnicity, smoking, alcohol consumption, medi-
cation and BMI. For longitudinal changes within the
same individual, a repeated measures model approach
will be employed.
A literature search was undertaken with the assistance of
the Biostatistics Unit (Faculty of Medicine and Health Sci-
ences, Stellenbosch University), and according to Donald et
al. [46], a case sample size of between n = 100–400 over a
3 months’ follow-up period was sufficiently powerful to se-
cure endothelial function measurement reproducibility and
statistical significance (1–2% effect size; 80% statistical
power and 5% significance). In our own pilot studies per-
formed in 2015 and early 2016, several cardiovascular risk
factors (BMI, HDL-cholesterol, blood pressure) were sig-
nificantly different between HIV-negative control and HIV-
positive participants, and HIV-infection was associated with
increased triglyceride levels and highly sensitive CRP values
(HIV-positive sample size: n = 110). We are therefore
confident that the proposed sample sizes will be sufficient
to secure sufficient statistical power.
At the time of writing, EndoAfrica has recruited a total
of 231 participants, of whom 60 are HIV-negative con-
trol and 171 are HIV-infected (ART naïve: n = 38). The
characteristics of the cohort at this stage show a mean
age of 39.23 ± 9.98 years, predominantly female partici-
pants (74.8%) with a high smoking prevalence (60.2%).
The study is on-going, and provisional completion date
is December 2018.
See Fig. 3 for a flow chart showing an overview of the
study and operating procedures.
Discussion
The EndoAfrica study will generate novel data in the
South African (and SSA) context. We are not aware of
any previous longitudinal studies in sub-Saharan Africa
undertaken to comprehensively assess cardiovascular
Fig. 3 Study overview and operating procedures. FMHS: Faculty of Medicine and Health Sciences; FMD: flow-mediated dilatation; IMT: intima-media
thickness; NHLS: National Health Laboratory Service
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risk and vascular endothelial changes in adults living
with and without HIV/AIDS. The repeated measures de-
sign of EndoAfrica will provide valuable insights into the
progression or regression of markers of cardiovascular
risk and disease in HIV-infected subjects. This informa-
tion can help to develop guidelines for the management
of cardiovascular health in patients with HIV-infection
in the local health care system. The findings of the
EndoAfrica study will furthermore contribute to the
current global knowledge base on HIV and cardiovascu-
lar disease, which is largely devoid of data from SSA.
The vascular and endothelial endpoints of the EndoA-
frica study will not only generate novel research data in
the South African context, but also have the potential to
predict future cardiovascular events. With a few excep-
tions, very little data are available on endothelial dys-
function in adult SSA populations in general, and in
HIV-infected populations in particular. The fact that
three independent, non-invasive imaging techniques,
complemented by the measurement of a battery of
serum biomarkers will be employed, can be regarded as
a strength of the study.
Possible limitations
The ethnic composition of the Western Cape Province
of South Africa, and hence of our study cohort, may
limit the possibility to extrapolate the findings to the rest
of the population. The majority of the population in
Cape Town and Worcester is of mixed ancestry, whilst
the majority of HIV-infected South Africans are ethnic
black Africans. The researchers will endeavour to recruit
as many black study participants as possible, and steps
to incorporate recruitment sites in other provinces
where more black participants can be included are cur-
rently undertaken. In addition, the follow-up period of
18 months may be too short to sufficiently determine
the progression of cardiovascular risk and vascular
changes. However, there have been previous prospective
studies employing similar or shorter follow-up periods
that could demonstrate disease progression or regression
(e.g. increased carotid IMT progression in HIV-infected
participants after 12 months [47], and regression of
endothelial dysfunction biomarkers after median
7.2 months ART [48]). The 18-month follow-up period
was chosen in view of the total project duration of
3 years. The EndoAfrica research team is now building
capacity and developing sustainable collaboration with
the aim to extend the follow-up period of the longitu-
dinal cohort beyond the lifetime of the initial project.
Recently, the South African Government announced
that all HIV-infected patients will immediately com-
mence with ART compared to the previous guidelines of
initiating ART at a CD4 count cut-off of 500 cells/μL.
This may limit our ability to recruit ART naïve
participants. Finally, the researchers need to take
cognizance of the fact that the FMD and IMT proce-
dures have certain limitations in terms of operator de-
pendency and inter-operator variability. Ensuring that
the same vascular regions are assessed in each partici-
pant at the 18 months’ follow-up visit is also a potential
challenge. In order to address this as far as possible, we
will limit the number of operators in the team, subject
them to intensive and expert training, and employ rigor-
ous verification and quality control measures by inde-
pendent experts in this field.
Conclusion
EndoAfrica is an important and relevant study in the
context of cardiovascular risk and vascular endothelial
dysfunction in HIV-infection. South Africa (and sub-
Saharan Africa) is the epicentre of the global HIV epi-
demic, yet very little is known about the prevalence of
cardiovascular risk factors and early vascular disease in
HIV-infected populations in this region. The EndoAfrica
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